Johnson & Johnson

Johnson & Johnson Strengthens Pipeline with First-of-its-Kind Oral Psoriasis Drug

Brett Shapiro - March 27, 2026

Johnson & Johnson Gains FDA Approval for Pioneering Oral Psoriasis Drug

angelina - March 19, 2026

Johnson & Johnson’s Ulcerative Colitis Treatment Demonstrates Sustained Efficacy in Long-Term Study

Brett Shapiro - February 22, 2026

Johnson & Johnson Shares: A Clinical Victory Meets Market Indifference

angelina - December 11, 2025

Johnson & Johnson’s Strategic Acquisition Fuels Investor Confidence

kashif hafeez - November 20, 2025